Palantir Faces Scaling Bottleneck Despite 85% Revenue Surge and 43.7% Net Margin Peak
GOOG•Palantir posted 85% year-over-year revenue growth yet its shares have slid 25% in the past year reflecting scaling constraints highlighted by just 70 US salespeople and a 49.2 price-to-sales multiple. The NHS contract in the UK is under review and the 43.7% net margin may face pressure if growth slows.
1. Revenue Growth and Salesforce Bottleneck
Palantir posted 85% year-over-year revenue growth while managing a 70-person US sales team, a scale that management describes as insufficient to meet demand, risking a slowdown in its rapid expansion at a 49.2 price-to-sales valuation.
2. UK NHS Contract Under Review
The National Health Service contract in the UK is undergoing a full review after a parliamentary committee flagged Palantir's public sector role as a vulnerability. This follows 84% US government revenue growth and highlights risks from client concentration and shifting political winds in allied markets.
3. Profitability at Five-Year Peak
Palantir's net margin reached 43.7%, its highest in five years, and its operating margin stood at 38.1%. Sustaining these peak margins may require heavier investment or price concessions if scaling challenges begin to impede revenue growth.
